Golimumab treatment for complicated uveitis

Clinical and Experimental Rheumatology

Volumn 31, Issue 2, 2013, Pages 0320-0321

  Miserocchi, Elisabetta ^a   Modorati, G ^a   Pontikaki, I ^b   Meroni, P L ^b   Gerloni, V ^b  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CORTICOSTEROID; ETANERCEPT; GOLIMUMAB; HLA B27 ANTIGEN; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; RITUXIMAB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADULT; CATARACT; CATARACT EXTRACTION; CLINICAL ARTICLE; DISEASE DURATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; GLAUCOMA; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LETTER; LOW DRUG DOSE; MALE; ONSET AGE; PRIORITY JOURNAL; RETINA MACULA EDEMA; RETINA SURGERY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY; IMMUNOLOGY; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UVEITIS; YOUNG ADULT;

EID: 84875767808     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. SAURENMANN RK, LEVIN AV, FELDMAN BM et al.: Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study. Arthritis Rheum 2007; 56: 647-57.
2. POWER WJ, RODRIGUEZ A, PEROZA-SERES M, FOSTER CS: Outcomes in anterior uveitis associated with the HLA-B27 haplotype. Ophthalmology 1998; 105: 1646-51.
3. SMOLEN JS, KAY J, DOYLE MK et al.: Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor a inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009; 374: 210-21.
4. EMERY P, FLEISCHMANN RM, MORELAND LW et al.: Golimumab, a human anti-tumor necrosis factor a monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naïve patients with active rheumatoid arthritis. Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2009; 60: 2272-83.
5. PETTY RE, SOUTHWOOD TR, MANNERS P et al.: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390-2.
6. THE STANDARDIZATION OF UVEITIS NOMENCLATURE (SUN) WORKING GROUP: Standardization of uveitis nomenclature for reporting clinical data. Results of the first International workshop. Am J Ophthalmol 2005; 140: 509-16.
7. CORDERO-COMA M, SALOM D, DIAZ-LLOPIS M, LOPEZ-PRATS MJ, CALLEJA S: Golimumab for uveitis. Ophthalmology 2011; 118 1892.
8. FOELDVARI I, NIELSEN S, KUMMERLE-DESCHNER J et al.: Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 2007; 34: 1146-50.
9. GERLONI V, PONTIKAKI I, GATTINARA M, FANTINI F: Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheum Dis 2008; 67: 1145-52.
10. MISEROCCHI E, PONTIKAKI I, MODORATI G, GATTINARA M, MERONI PL, GERLONI V: Anti- CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimm Rev 2011; 11: 35-9.